Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia

  • Authors:
    • Qingxiao Hong
    • Xiaoying Chen
    • Huadan Ye
    • Annan Zhou
    • Yuting Gao
    • Danjie Jiang
    • Xiaodong Wu
    • Bingru Tian
    • Youfen Chen
    • Ming Wang
    • Jiping Xie
    • Yongming Xia
    • Shiwei Duan
  • View Affiliations

  • Published online on: March 9, 2016     https://doi.org/10.3892/ol.2016.4317
  • Pages: 2851-2856
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a tumor suppressor gene that is associated with the risk of developing acute myeloid leukemia (AML). However, the association between the methylation status of the MGMT promoter and the chemotherapeutic outcomes of patients with AML remains unknown. In the present study, 30 bone marrow samples derived from patients with AML were collected prior and subsequent to chemotherapy. The methylation status of the MGMT promoter in the bone marrow specimens was determined by methylation‑specific polymerase chain reaction. The results indicated that the methylation status of the MGMT promoter was influenced by different chemotherapeutic regimens. The MGMT methylation status of M4 patients (3 out of 6) were more chemosensitive, compared with that of patients with other AML subtypes (M1, 1 out of 3; M2, 0 out of 8; M3, 3 out of 7; M5, 0 out of 3; and M6, 1 out of 3). Age‑based analysis revealed that the group aged ≤60 years (7 out of 24 patients) exhibited more methylation changes than patients aged >60 years (1 out of 6). Male patients (4 out of 13) were more susceptible to chemotherapy‑induced methylation changes than female patients (4 out of 17). Thus, the methylation status of the MGMT promoter may serve as a potential biomarker to predict the therapeutic outcomes in male AML patients. However, further studies in larger sample sets are required to confirm the present findings.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 11 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hong Q, Chen X, Ye H, Zhou A, Gao Y, Jiang D, Wu X, Tian B, Chen Y, Wang M, Wang M, et al: Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia. Oncol Lett 11: 2851-2856, 2016.
APA
Hong, Q., Chen, X., Ye, H., Zhou, A., Gao, Y., Jiang, D. ... Duan, S. (2016). Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia. Oncology Letters, 11, 2851-2856. https://doi.org/10.3892/ol.2016.4317
MLA
Hong, Q., Chen, X., Ye, H., Zhou, A., Gao, Y., Jiang, D., Wu, X., Tian, B., Chen, Y., Wang, M., Xie, J., Xia, Y., Duan, S."Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia". Oncology Letters 11.4 (2016): 2851-2856.
Chicago
Hong, Q., Chen, X., Ye, H., Zhou, A., Gao, Y., Jiang, D., Wu, X., Tian, B., Chen, Y., Wang, M., Xie, J., Xia, Y., Duan, S."Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia". Oncology Letters 11, no. 4 (2016): 2851-2856. https://doi.org/10.3892/ol.2016.4317